Last reviewed · How we verify
FVIII Replacement
Recombinant FVIII replacement to correct FVIII deficiency
Recombinant FVIII replacement to correct FVIII deficiency Used for Hemophilia A.
At a glance
| Generic name | FVIII Replacement |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Coagulation factor replacement |
| Target | Factor VIII |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | Phase 2 |
Mechanism of action
FVIII replacement therapy is used to treat hemophilia A by replacing the deficient clotting factor VIII.
Approved indications
- Hemophilia A
Common side effects
- Inhibitor formation
- Allergic reactions
- Headache
Key clinical trials
- A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) (PHASE3)
- Von Willebrand Factor in Pregnancy (VIP) Study
- A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) (PHASE3)
- Drug Use Investigation of Kovaltry in Hemophilia A Patients
- Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis (NA)
- Data Registry in Chinese Hemophilia A and B Patients
- POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies (PHASE4)
- Type 3 Von Willebrand International Registries Inhibitor Prospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FVIII Replacement CI brief — competitive landscape report
- FVIII Replacement updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI